Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms

International Journal of Cancer

Volumn 134, Issue 3, 2014, Pages 731-739

  Wöll, Stefan ^a   Schlitter, Anna Melissa ^b   Dhaene, Karl ^c   Roller, Marc ^a   Esposito, Irene ^b   Sahin, Ugur ^d   Türeci, Özlem ^a  

^a Ganymed Pharmaceuticals AG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Algemeen Stedelijk Ziekenhuis   (Belgium)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Claudin 18 splice variant 2; immunohistochemistry; pancreatic neoplasms

Indexed keywords

CANCER ANTIBODY; CLAUDIN 18.2; IMAB362 ANTIBODY; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ACINAR CELL CARCINOMA; ARTICLE; CANCER STAGING; CLINICAL EVALUATION; CONTROLLED STUDY; FEASIBILITY STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NEUROENDOCRINE TUMOR; PANCREAS ADENOCARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING;

EID: 84887990527     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28400     Document Type: Article

References (28)

1. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer (Oxford, England: 1990) 2010; 46: 765-81.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Seufferlein T, Bachet JB, Van Cutsem E, et al. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl 7): vii33-vii40.
4. Bray F, Ren JS, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013; 132: 1133-45.
5. Orphanet Report Series-Prevalence of rare diseases: Bibliographic data, May 2012, Number 1.
6. Sant M, Allemani C, Santaquilani M, et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer (Oxford, England: 1990) 2009; 45: 931-91.
7. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Medicine 2011; 364: 1817-25.
8. Burris HA, III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
9. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-6.
10. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28: 3617-22.
11. Kindler HL, Wroblewski K, Wallace JA, et al. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Investig New Drugs 2012; 30: 382-6.
12. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010; 28: 3605-10.
13. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 2231-7.
14. Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 2008; 14: 7624-34.
15. Tureci O, Koslowski M, Helftenbein G, et al. Claudin-18 gene structure, #regulation, and expression is evolutionary conserved in mammals. Gene 2011; 481: 83-92.
16. Karanjawala ZE, Illei PB, Ashfaq R, et al. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol 2008; 32: 188-96.
17. Soini Y, Takasawa A, Eskelinen M, et al. Expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma: association with features of differentiation. J Clin Pathol 2012; 65: 431-6.
18. Tanaka M, Shibahara J, Fukushima N, et al. Claudin-18 is an early-stage marker of pancreatic carcinogenesis. J Histochem Cytochem 2011; 59: 942-52.
19. Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumors of the digestive system, 4 ed. Lyon: IARC, 2010.
20. Landis JR, Koch GG,. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 1977; 33: 363-74.
21. Niimi T, Nagashima K, Ward JM, et al. claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol 2001; 21: 7380-90.
22. Liu H, Shi J, Anandan V, et al. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas. Arch Pathol Lab Med 2012; 136: 601-9.
23. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-97.
24. Scagliotti GV, Novello S, von Pawel J,. The emerging role of MET/HGF inhibitors in oncology. Cancer Treatment Rev 2013; 39: 793-801.
25. Seufferlein T, Bachet JB, Van Cutsem E, et al. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl 7): vii33-vii40.
26. Lee JH, Kim KS, Kim TJ, et al. Immunohistochemical analysis of claudin expression in pancreatic cystic tumors. Oncol Rep 2011; 25: 971-8.
27. Ito T, Kojima T, Yamaguchi H, et al. Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells. J Cell Biochem 2011; 112: 1761-72.
28. Sanada Y, Hirose Y, Osada S, et al. Immunohistochemical study of claudin 18 involvement in intestinal differentiation during the progression of intraductal papillary mucinous neoplasm. Anticancer Res 2010; 30: 2995-3003.